International Stem Cell (ISCO) Change in Receivables (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Change in Receivables of -$292000.0 for Q4 2025, down 177.25% year-over-year from $378000.0 in Q4 2024, and down 239.53% quarter-over-quarter from -$86000.0 in Q3 2025.
International Stem Cell (ISCO) Change in Receivables (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Change in Receivables for 16 consecutive years, with -$292000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables fell 177.25% year-over-year to -$292000.0; the TTM figure through Dec 2025 stood at -$335000.0 (down 169.21% YoY), while the FY2025 annual figure was -$335000.0, down 169.21% from the prior year.
- Change in Receivables declined to -$292000.0 in Q4 2025 per ISCO's latest filing, from -$86000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $378000.0 in Q4 2024 and bottomed at -$292000.0 in Q4 2025.
- Historically, Change in Receivables has averaged $16000.0 across 5 years, with a median of $8000.0 in 2021.
- On a YoY basis, Change in Receivables climbed as much as 784.62% in 2024 and fell as far as 622.22% in 2024.
- International Stem Cell's Change in Receivables stood at $176000.0 in 2021, then jumped by 81.82% to $320000.0 in 2022, then slumped by 121.88% to -$70000.0 in 2023, then soared by 640.0% to $378000.0 in 2024, then plunged by 177.25% to -$292000.0 in 2025.
- Business Quant data shows ISCO's Change in Receivables at -$292000.0 in Q4 2025, -$86000.0 in Q3 2025, and $250000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -292,000.00 |
| Dec 31, 2025 | -292,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | 250,000.00 |
| Jun 30, 2025 | 250,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Sep 30, 2024 | -130,000.00 |
| Sep 30, 2024 | -130,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Dec 31, 2023 | -70,000.00 |
| Dec 31, 2023 | -70,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Sep 30, 2023 | -18,000.00 |